The infrastructure behind regulated AI that saves lives. That is SRI Ventures.
A venture builder operating across defence, health, space, and energy — built on sovereign institutional relationships, granted patents, and a regulatory playbook established through three decades of verified first-mover clearances and hard lessons learnt.
$402M Verified Exit Value — Medica Group plc (LSE) and Synbiotix
$1B+ Economic Impact
World-First: MHRA Autonomous AI Approval for Clinical Diagnosis
MHRA World-First for Automous AI for chest x-rays
Prix Galien International 2024 — Highest Accolade in Life Sciences
Prix Galien 2024 the highest accolade in Life Sciences
Why Regulated AI Needs a Different Infrastructure Layer
Three Decades of First-Mover Regulatory Approvals
Granted Patent Portfolio Across Health and Defence
AI Deployment Architecture Built for Institutional Procurement
Simon Rasalingham secured the world's inaugural MHRA autonomous clinical AI approval and one of the first FDA 510(k) clearances in its class. Every SRI venture is built on that foundation — established submission strategies, deep regulatory relationships, and a track record of first-mover approvals across multiple jurisdictions. Partners access a regulatory capability that takes most organisations a decade to develop, from the first day of engagement.
Every SRI venture is built on granted intellectual property that provides structural commercial protection. In regulated procurement environments where timelines are measured in years, an active patent portfolio provides the long-term defensibility that institutional partners require. Partners are not building on a roadmap — they are building on a foundation with enforceable legal weight from day one.
The barrier to regulated AI deployment is rarely the science. It is procurement architecture — committees structured for process compliance rather than outcome accountability. SRI was built to resolve that gap. The regulatory playbook, the patent architecture, and the institutional relationships exist to make cost-negative deployment the default: systems that save money or lives from day one of operation, removing the structural basis for deferral.
Two Verified Exits. A Structural Lesson Applied to What Comes Next.
Medica Group plc
LSE Listed Exit
Exited at £269M ($339M). Demonstrated the full discipline of building a healthcare technology company from founding through institutional governance to deliver a business worthy of public markets, and a recommended cash acquisition.
Synbiotix
£50M Acquisition
Regulated SaaS at scale. Recurring revenue model. Commercial distribution across healthcare facilities management. The capability transferred: regulated software commercialisation and repeatable revenue architecture.
Behold.ai
Behold.ai — Regulatory and Clinical Foundation
World-first autonomous AI diagnostic — MHRA approved, FDA 510(k) cleared, CQC registered. Winner of the Prix Galien International 2024. Three years of live NHS deployment with zero missed lung cancers. The operating company entered administration in January 2025 following the UK government's AI Diagnostic Fund procurement process, as reported by Digital Health. Now operating under new ownership, the technical foundation of SRI's current platform is built on these learnings.
$402M exit value
Total economic value generated for the UK economy: over $1 billion, calculated using HM Treasury Green Book methodology.
The verified economic record
$402M
$100M–$150M
$50M–$80M
$1B+
Combined enterprise value at exit: Medica Group plc (LSE) and Synbiotix trade sale
Derived using HM Treasury Green Book 2.5× multiplier applied to direct exit value — consistent with UKRI impact methodologies
Value from backlog reduction, diagnostic turnaround improvement, and cost avoidance across NHS Trust deployments
Tax contribution generated across operating lifecycles including corporation tax, VAT, business rates, and capital gains
Economic multiplier methodology consistent with HM Treasury Green Book guidance and UKRI impact assessment frameworks.
Institutional Partnerships and Verified Research Credentials
Institutional Partners
Exclusive IP Licence
Following a competitive evaluation, SRI was selected as the exclusive licensee for a foundational oncology radiomics IP portfolio. The licensing decision reflects institutional assessment of regulatory track record and technical deployment capability.
Signed Defence Partnership
A formal signed agreement with a NATO-certified defence and security organisation provides access to authenticated combat RF datasets that underpin AI training in counter-UAS applications. This data is not commercially available and cannot be replicated through open-source collection.
Academic Research Partnership
A confirmed principal investigator relationship at a leading Qatari research university anchors the UK-Qatar healthcare AI regulatory framework programme. This partnership provides both academic validation and sovereign data infrastructure access across the Gulf Cooperation Council.
Clinical Data Consortium
MOUs executed in early 2026 with leading conflict trauma and rehabilitation centres provide access to a retrospective clinical corpus. This dataset — covering acute battlefield trauma at scale — does not exist in any commercial or academic AI training repository.
Defence Go-to-Market
As a founding member of the Grail Alliance, SRI has access to a structured go-to-market pathway across allied defence procurement systems. This provides direct routes to sovereign defence customers in allied nations without requiring individual country-by-country business development from zero.
Legislative & Policy Access
Active relationships at senior legislative and policy level across four sovereign governments provide positioning access to the major defence and health research funding programmes in each jurisdiction — including UK defence & health procurement bodies, US federal research agencies, Qatari national research funding, and Ukrainian sovereign medical and defence priorities.
Scientific Verification
Published Research
7 peer-reviewed publications with over 100 citations in medical AI, covering autonomous chest X-ray triage, CT head acute triage, and precision oncology radiomics. Full bibliography available on Google Scholar.
Core Research Areas
Validation of AI for rule-out of normal chest X-rays; acute triage of CT head scans; precision oncology radiomics for treatment selection in NSCLC.
Regulatory Firsts
First autonomous AI to rule out normal chest X-rays to receive MHRA approval, integrated with CQC registration in live NHS settings. Deployed internationally during COVID-19 with a major South Asian hospital network.
Clinical Standards
FDA 510(k) clearance for triaging life-critical findings. ISO 13485 QMS Certification. The first AI provider to achieve CQC registration for autonomous clinical diagnosis.
The SRI Platform: Regulated AI Infrastructure Across Health and Defence
Regulatory Expertise
SRI brings established relationships with the major regulatory bodies across health and defence — built through prior approvals and active submissions in multiple jurisdictions. Customers and partners benefit from a regulatory capability that takes most organisations a decade to develop, available from the first day of engagement.
Proven AI and ML Capability
SRI's AI and machine learning architecture has been validated in live clinical and defence environments, delivering the performance standards required for regulated deployment. Partners and customers access a technical foundation that has already met the bar — rather than building toward it.
Patented IP Portfolio
Every venture is built on granted, registered intellectual property that provides customers and partners with durable commercial protection. What is built on the SRI platform carries enforceable legal weight from day one, ensuring long-term defensibility in regulated procurement markets.
Sovereign Funding Access
SRI maintains active positioning across UK, US, European, and Gulf sovereign funding programmes, enabling non-dilutive capital to support ventures at the stages of highest technical risk. Partners and customers who engage with SRI gain access to a grant positioning capability that would take years to build independently.
Senior Expertise Across Domains
SRI brings together senior capability in machine learning, regulatory affairs, and clinical and defence domains — deployed across ventures rather than siloed within them. Customers and partners gain access to a depth and breadth of expertise that a single-venture team cannot replicate.
Pipeline
Where the platform goes next
Space
The regulatory and IP architecture SRI has developed across health and defence is directly transferable to the emerging regulated AI frameworks taking shape in the space sector. SRI is actively assessing applications of its platform — including autonomous systems, predictive logistics, and life-critical AI — to sovereign and commercial space programmes.
Energy
Critical national infrastructure in the energy sector faces a regulatory environment with structural similarities to health and defence — high consequence of failure, long procurement cycles, and increasing regulatory scrutiny of AI-driven decision-making. SRI's platform is being scoped for application in this domain.
Pipeline ventures are in active scoping. Engagement at this stage is by direct conversation only.
Work With Us
Infrastructure for Regulated AI for Customers
Capabilities that Compound for Partners
SRI does not build pilots. Every engagement is structured as cost-negative infrastructure: deployed to generate measurable savings or clinical outcomes from day one. A system that demonstrably reduces cost or improves survival outcomes from first deployment creates a different procurement conversation — one grounded in outcome accountability rather than process approval. That is the structural position SRI builds into every venture — not a trial, not a proof of concept, not a committee recommendation. If the numbers do not demonstrate net cost savings or measurable outcome improvement from day one, SRI does not bring it to market.
You have capabilities that compound with ours. SRI works with academic institutions, defence contractors, clinical networks, and sovereign partners whose data, domain expertise, or market access strengthens the platform across all ventures. Current active consortia span the United Kingdom, United States, Qatar, and Ukraine.
Get in touch
Direct contact for business development, investment, and media enquiries.
Partnerships & Business Development
cbdo@rasalingham.com
Investment Enquiries
cfo@rasalingham.com
Press & Media
cmo@rasalingham.com
This site does not constitute an offer of securities. Venture-specific materials are available to authorised recipients only.